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Abstract
Background/Aims: Estrogen signalling plays an important role in vascular biology as it 
modulates vasoactive and metabolic pathways in endothelial cells. Growing evidence has also 
established microRNA (miRNA) as key regulators of endothelial function. Nonetheless, the 
role of estrogen regulation on miRNA profile in endothelial cells is poorly understood. In this 
study, we aimed to determine how estrogen modulates miRNA profile in human endothelial 
cells and to explore the role of the different estrogen receptors (ERα, ERβ and GPER) in 
the regulation of miRNA expression by estrogen. Methods: We used miRNA microarrays 
to determine global miRNA expression in human umbilical vein endothelial cells (HUVEC) 
exposed to a physiological concentration of estradiol (E2; 1 nmol/L) for 24 hours. miRNA-
gene interactions were computationally predicted using Ingenuity Pathway Analysis and 
changes in miRNA levels were validated by qRT-PCR. Role of ER in the E2-induced miRNA 
was additionally confirmed by using specific ER agonists and antagonists. Results: miRNA 
array revealed that expression of 114 miRNA were significantly modified after E2 exposition. 
Further biological pathway analysis revealed cell death and survival, lipid metabolism, 
reproductive system function, as the top functions regulated by E2. We validated changes 
in the most significantly increased (miR-30b-5p, miR-487a-5p, miR-4710, miR-501-3p) and 
decreased (miR-378h and miR-1244) miRNA and the role of ER in these E2-induced miRNA 
was determined. Results showed that both classical, ERα and ERβ, and membrane-bound ER, 
GPER, differentially regulated specific miRNA. In silico analysis of validated miRNA promoters 
identified specific ER binding sites. Conclusion: Our findings identify differentially expressed 
miRNA pathways linked to E2 in human endothelial cells through ER, and provide new insights 
by which estrogen can modulate endothelial function.
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Introduction
17β-Estradiol (E2) is the most important estrogen, which exerts its action mainly through 
activation of estrogen receptors (ER) present in different tissues, including endothelium 
[1]. Endothelial cells are involved in the regulation of vascular function and express both 
types of nuclear estrogen receptors (ERα and ERβ) as well as the G protein-coupled estrogen 
receptor (GPER) [2].
Women during their fertile ages present less incidence of cardiovascular diseases than 
age-matched men and this advantage disappears after menopause, attributing a beneficial 
effect to estrogens [3]. Protective effects by estrogen on cardiovascular system have been 
related to increased vasodilation, anti-inflammatory action, regulation of vascular smooth 
muscle cell proliferation, and attenuation of atherosclerotic processes [4]. In this regard, 
the E2-mediated vasoprotective role through an increase of endothelial-derived factors has 
been described to be ER-dependent [5-7].
microRNA (miRNA) are small, non-coding RNA enrolled in gene expression regulation 
at post-transcriptional level and are predicted to regulate two-thirds of the human genome, 
suggesting that miRNA modulate physiological relevant processes [8]. miRNA regulate 
protein translation by targeting their complementary messenger RNA (mRNA) [9] and by 
repressing translation or degrading target mRNA. Most miRNA are located within the cell, 
although some of them have also been found circulating in body fluids [10]. Nowadays, there 
are many studies focused in their role in different clinical conditions, including cardiovascular 
diseases, and their potential as clinical biomarkers [11, 12].
The effects of E2 on gene [5, 13] and protein expression [14] have already been reported 
in endothelial cells. Few recent studies in gynaecological cancer research have described 
an association of miRNA and estrogen signalling. Most of them have described the role of 
miRNA to regulate ER expression and estrogen-associated molecules [15, 16]. How E2 may 
interfere with the whole miRNA expression profile in the cardiovascular system is largely 
unknown. In this regard, our study aims to determine changes in miRNA expression profile 
in cultured human umbilical vein endothelial cells (HUVEC) exposed to physiological 
concentration of E2. By using microarray technology, we sought to provide new information 
about the molecular mechanisms implicated in the E2 regulation of vascular function. We 
also investigate the implication of different ER in E2-dependent miRNA regulation.
Materials and Methods
Cell culture and experimental design
Primary HUVEC cultures were obtained by collagenase treatment of human umbilical cord veins from 
Hospital Clínico of Valencia as previously described [17]. Briefly, HUVEC were obtained from umbilical veins 
by enzymatic digestion with 0.1 mg/mL collagenase (Life Technologies, Carlsbad, CA, USA) and cultured 
in Medium 199 (Sigma-Aldrich, Tres Cantos, Madrid, Spain) supplemented with 20% fetal bovine serum 
(GIBCO, Barcelona, Spain), endothelial cell growth supplement (Sigma-Aldrich) and heparin sodium salt 
(Sigma-Aldrich) at 37 ºC with 5% CO2. Cells were identified as endothelial by their characteristic cobblestone 
morphology and the presence of von Willebrand factor by immunocytochemistry using a specific antibody 
(F-3520; Sigma-Aldrich) as previously described [18]. HUVEC from passages 3 to 4 were seeded onto 
gelatin-coated 6-well plates. When they reached confluence, culture medium was exchanged for a phenol 
red-free Medium 199 (Sigma-Aldrich) supplemented with 20% charcoal/dextran-treated fetal bovine 
serum (GIBCO) to avoid any steroid activity and maintained for 24 hours.
Cells were exposed for 24 h to 1 nmol/L of E2 (Sigma-Aldrich). In some experiments, to study the role of 
sex hormone receptors, cells were previously exposed (60 minutes before E2) to the unspecific antagonist of 
ERα and ERβ, ICI 182780 (1 μmol/L; Biogen, Madrid, Spain), the specific ERα antagonist methyl-piperidino-
pyrazole (MPP) (1 μmol/L; Tocris Bioscience, Ellisville, MI, USA) and to the specific GPER antagonist G15 (1 
μmol/L; Tocris Bioscience). In another set of experiments, cells were exposed for 24 hours to the selective 
ERα agonist PPT (1 nmol/L; Tocris Bioscience), the selective ERβ agonist DPN (1 nmol/L; Tocris Bioscience), 
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or the selective GPER agonist G1 (1 nmol/L; 
Tocris Bioscience). Control cells were 
exposed to the same vehicle of cells treated 
with E2 (0.1% etanol) or antagonist (0.1% 
DMSO). All concentrations and times selected 
were chosen taking into account previous 
studies [5, 19, 20]. A schematic workflow of 
the experimental design is provided in Fig. 1.
The research protocol was approved by 
the Ethical Committee of Clinical Research 
of the INCLIVA, Hospital Clínico of Valencia, 
Spain, conforms with the principles outlined 
in the Declaration of Helsinki, and written 
informed consent was obtained from all 
donors.
RNA isolation and microRNA expression 
analysis
To perform microarray experiment, 
HUVEC from 12 separate cultures were 
exposed to control (0.1% ethanol) and 1 
nmol/L E2 treatments for 24 h. Total RNA 
including small non-coding RNA was extracted 
by using the QIAzol reagent and miRNeasy 
Mini kit (Qiagen, L’Hospitalet de Llobregat, 
Spain) following the manufacturer’s 
instructions. RNA extracted from 3 control- or 3 E2-treated cultured flasks obtained from three different 
cultures were pooled, achieving four biological replicates of the control and four that were treated with E2. 
Therefore, a total number of 8 microarrays were developed (4 control pools, named C1, C2, C3, C4 and 4 E2-
treated pools named E1, E2, E3 and E4).
The concentration and purity of the RNA obtained was measured as the OD260/280 ratio using a 
GeneQuant Pro spectrophotometer (GE Healthcare, Madrid, Spain). RNA integrity was determined by 
capillary electrophoresis using an RNA 6000 Nano Lab-on-a-Chip kit and a Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA). Only RNA extracts with an integrity value of 7 or higher were used for 
further analysis.
Small non-coding RNA expression profiling was performed using a GeneChip miRNA 4.0 Array 
(Affymetrix, Santa Clara, CA, USA). Microarray experiments were conducted according to the manufacturer’s 
protocol. Briefly, 300 ng of total RNA was labelled with a FlashTag Biotin HSR RNA Labeling kit from 
Genisphere. The labelling reaction was hybridized onto the miRNA array in an Affymetrix Hybridization 
Oven 645 at 48°C and 60 rpm for 18h. The arrays were stained using a Fluidics Station 450 with the fluidics 
script FS450_0002 (Affymetrix) and then scanned on a GeneChip Scanner 3, 000 7G (Affymetrix), using the 
GeneChip Command Console Software supplied by Affymetrix to perform gene expression analysis. miRNA 
probe outliers were defined and further analysed as manufacturer’s instructions, and quality control, as 
well as data summarization and normalization, was carried out using the web-based miRNA QC Tool (www. 
affymetrix.com).
Resulting data files (.cel) were used to analyse significant differences in miRNA expression profile 
between E2 and control groups using Partek Genomic Suite (Partek Inc., St Louise, MO, USA) [21]. Partek 
Genomic Suite was also used to identify global differences between samples by Principal Component 
Analysis (PCA) measurement. Distance between plotted samples is related to similarity between them. 
Hierarchical Cluster was determined to analyse expression profiles of different samples, in which the 
branches represented in a dendrogram that are close to each other had similar miRNA expression patterns.
Analysis of miRNA-predicted target interaction
miRNA significantly regulated by estrogen were analysed using Ingenuity Pathways Analysis (IPA) 
software (Ingenuity Systems, Redwood City, CA, USA; Winter release 2016) as previously described in [5, 22]. 
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This software uses computational algorithms to identify miRNA-targets as well as putative cellular networks 
between the predicted targets. IPA microRNA Target Filter tool enables prioritization of experimentally 
validated and predicted mRNA targets according to three different miRNA target prediction programs 
(TargetScan, miRecords and Ingenuity Knowledge Base) and the available database of experimentally 
supported miRNA targets TarBase.
Quantitative real-time PCR
The TaqMan miRNA Assay system (Applied Biosystems, Foster City, CA, USA) was used to validate 
changes in miRNA levels. For reverse transcription (RT) reactions, RNA (300 ng) was reverse transcribed 
using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s 
instructions. Specific RT primers from each assay were added to 15 μL reaction volumes. miRNA levels were 
determined by quantitative real-time PCR (qRT-PCR) analysis using an ABI Prism 7900 HT Fast Real-Time 
PCR System (Applied Biosystems). Gene-specific primer pairs and probes (Applied Biosystems) for miR-
30b-5p (000602), miR-4710 (463602_mat), miR-1244 (002791), miR-487a-5p (467005_mat), miR-501-3p 
(002435), miR-378h (464554_mat), were used together with TaqMan Universal PCR Master Mix (Applied 
Biosystems) and 1 μL of reverse-transcribed product in 20 μL reaction volumes. PCR conditions were 
10 min at 95 °C for enzyme activation, followed by 60 two-step cycles (15 s at 95 °C; 1 min at 60 °C). The 
levels of RNU48 (001006) expression were measured in all samples to normalize differences in RNA input, 
RNA quality, and reverse transcription efficiency. Each sample was analysed in triplicate, and the expression 
was calculated according to the 2−ΔΔCt method.
Analysis of miRNA location and putative ER binding sites in the regulatory region of the miRNA precursors
miRIAD software, a web search tool designed to obtain integrated information about intragenic miRNA 
and their host genes, was used to know E2-induced miRNA location [23]. Moreover, in silico analysis of 
ER putative binding sites within the regulatory region of miRNA was performed by using available online 
bioinformatic tools. We used miRStart database [24] and Promoter 2.0 Prediction Server [25] to predict the 
transcription start site (TSS) of the specific miRNA. When using Promoter 2.0, sequences scoring above 1.0 
(highly likely prediction), which contain about 95% of true promoter sequence, were chosen as the miRNA 
precursor TSS. Gene and up-stream sequences were obtained from Ensembl (release 87; Dec 2016) [26]. 
Then, JASPAR 2016 server was used to predict ERα and ERβ binding sites for binding motifs drawn from the 
JASPAR database [27].
Statistical analysis
Data from microRNA expression analysis were analysed by paired t-test. For multiple comparisons, 
ANOVA was used to determine the difference between groups. When an interaction effect was found, multiple 
comparisons using Bonferroni’s test was performed. Data are expressed as mean ± SEM, and results were 
considered as significantly different using a p<0.05. The statistical analysis was performed using PRISM 5 
software (GraphPad Software Inc., San Diego, CA, USA).
Results
Global analysis of miRNA expression data by PCA and hierarchical clusters
Changes in miRNA expression profile induced by E2 indicated a global alteration of 
miRNA, and were analysed and compared to control samples by principal component analysis 
(PCA) and Hierarchical clustering (Fig. 2). PCA was performed to globally view the groups 
among the 8 samples in terms of the expression profile. Although samples are dispersed 
with each other, results showed E2-treated and non-treated (control) pools enclosed in 
two differentiated clusters, underlying differences in the expression patterns between both 
groups (Fig. 2A). This indicates that miRNA have similar and consistent expression patterns 
within each group, but are distinct from each other, demonstrating the profound impact of 
E2 treatment on miRNA expression in endothelial cells. Hierarchical clustering showed large 
similarities among different treated samples. However, 298 probe sets of small non-coding 
RNA were differentially expressed between both groups (Fig. 2B).
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We next explored those miRNA that were significantly 
regulated by 1 nmol/L E2, and we found that 114 miRNA 
were differentially expressed compared to control 
cells, using a cut-off with adjusted p values of < 0.05. In 
particular, 70 miRNA were up-regulated and 44 down-
regulated in HUVEC treated with E2 compared to control 
cells (Table 1). Microarray chips contained 2578 human 
mature miRNA probes, and therefore, approximately 
4.4 % of mature human miRNA were regulated by E2 in 
endothelial cells.
In silico analysis of gene regulation by E2-modified 
miRNA
IPA miRNA Target Filter tool was used to identify 
networks and pathways of the miRNA expression profile 
modified in HUVEC by E2. This software identified 
112 of the 114 miRNA significantly modified by E2. 
Analysis of those 112 miRNA lead a total of 21748 either 
predicted or validated mRNA targets. In order to adopt 
a restrictive approach, we further filtered those mRNA 
targets by choosing only “the experimentally observed” 
and “highly predicted” target correlations, obtaining 
5126 mRNA targeted by 112 miRNA. Using the selected 
miRNA-target pairing as an input, IPA revealed the most 
impacted biological processes, including cell death and 
survival, cellular assembly and organization, molecular 
transport, cell cycle, as well as cellular morphology and 
movement (listed in Table 2). Lipid and carbohydrate 
metabolism have also been included among the most 
regulated networks. In addition, reproductive, auditory-vestibular and cardiovascular 
system development and function appeared also as regulated by E2-dependent miRNA. 
Relationships to diseases and disorders including infection diseases, gastrointestinal disease, 
cancer, cardiovascular diseases and dermatological diseases were also noted.
Fig. 2. Principal component analysis (PCA) and hierarchical 
cluster of E2 treated HUVEC. (A) PCA of miRNA expression profile 
of HUVEC treated with vehicle (0.1% ethanol) or E2 (1 nmol/L) 
for 24 h. (B) Hierarchical cluster of differentially expressed miRNA 
in HUVEC treated with vehicle (0.1 % ethanol) or E2 (1 nmol/L). 
Each column represents an individual probe set and each row 
represents a pool of cells. Control sample pools (C; n=4) and E2 


































Table 1. Significant regulated miRNA 
in E2-exposed HUVEC. The 114 miRNA 
significantly regulated by 1 nmol/L 
E2 were ordered according to their 
statistical significance in the microarray 
analysis. The list include miRNA that 
were both up-regulated (positive fold-
change) and down-regulated (negative 
fold-change) by E2
 
miRNA ID Accession p-value Fold change 
hsa-miR-6754-3p MIMAT0027409 0,0013 1,57 
hsa-miR-6839-3p MIMAT0027581 0,0023 -1,14 
hsa-miR-501-3p MIMAT0004774 0,0025 1,77 
hsa-miR-548al MIMAT0019024 0,0037 -1,20 
hsa-miR-219a-5p MIMAT0000276 0,0038 1,16 
hsa-miR-6721-5p MIMAT0025852 0,0041 1,34 
hsa-miR-548c-3p MIMAT0003285 0,0047 1,13 
hsa-miR-3170 MIMAT0015045 0,0055 -1,15 
hsa-miR-577 MIMAT0003242 0,0057 -1,18 
hsa-miR-526b-3p MIMAT0002836 0,0059 -1,15 
hsa-miR-1244 MIMAT0005896 0,0059 -1,76 
hsa-miR-3975 MIMAT0019360 0,0061 1,24 
hsa-miR-487a-5p MIMAT0026559 0,0062 1,94 
hsa-miR-6866-3p MIMAT0027633 0,0073 -1,24 
hsa-miR-623 MIMAT0003292 0,0077 -1,16 
hsa-miR-6871-3p MIMAT0027643 0,0080 -1,14 
hsa-miR-26a-5p MIMAT0000082 0,0085 1,20 
hsa-miR-6848-5p MIMAT0027596 0,0093 1,21 
hsa-miR-6750-3p MIMAT0027401 0,0098 1,35 
hsa-miR-6884-3p MIMAT0027669 0,0108 1,47 
hsa-miR-4797-3p MIMAT0019973 0,0109 1,09 
hsa-miR-520g-3p MIMAT0002858 0,0109 1,29 
hsa-miR-1224-3p MIMAT0005459 0,0113 -1,21 
hsa-miR-1973 MIMAT0009448 0,0123 -1,31 
hsa-miR-4491 MIMAT0019026 0,0130 1,22 
hsa-miR-3120-5p MIMAT0019198 0,0142 1,14 
hsa-miR-1303 MIMAT0005891 0,0144 1,18 
hsa-miR-3689f MIMAT0019010 0,0145 1,30 
hsa-miR-6782-5p MIMAT0027464 0,0149 1,35 
hsa-miR-937-3p MIMAT0004980 0,0152 -1,13 
hsa-miR-7-2-3p MIMAT0004554 0,0163 -1,15 
hsa-miR-4679 MIMAT0019763 0,0165 1,16 
hsa-miR-922 MIMAT0004972 0,0165 1,18 
hsa-miR-378h MIMAT0018984 0,0169 -1,72 
hsa-miR-4429 MIMAT0018944 0,0174 -1,40 
hsa-miR-5008-3p MIMAT0021040 0,0174 1,23 
hsa-miR-7158-5p MIMAT0028226 0,0196 1,44 
hsa-miR-4462 MIMAT0018986 0,0197 1,42 
hsa-miR-1296-5p MIMAT0005794 0,0199 1,39 
hsa-miR-512-3p MIMAT0002823 0,0364 1,11 
hsa-miR-5739 MIMAT0023116 0,0365 1,18 
hsa-miR-3124-5p MIMAT0014986 0,0365 1,58 
hsa-miR-4710 MIMAT0019815 0,0379 1,88 
hsa-miR-1294 MIMAT0005884 0,0382 1,13 
hsa-miR-6734-5p MIMAT0027369 0,0385 1,53 
hsa-miR-3622b-3p MIMAT0018006 0,0396 1,23 
hsa-miR-4680-3p MIMAT0019765 0,0399 -1,09 
hsa-miR-553 MIMAT0003216 0,0405 -1,20 
hsa-miR-876-5p MIMAT0004924 0,0406 1,20 
hsa-miR-6800-3p MIMAT0027501 0,0415 1,67 
hsa-miR-6747-3p MIMAT0027395 0,0418 -1,21 
hsa-miR-3125 MIMAT0014988 0,0421 -1,17 
hsa-miR-6512-5p MIMAT0025480 0,0422 1,11 
hsa-miR-6841-5p MIMAT0027584 0,0431 -1,17 
hsa-miR-508-3p MIMAT0002880 0,0435 -1,09 
hsa-miR-1302 MIMAT0005890 0,0439 -1,29 
hsa-miR-506-5p MIMAT0022701 0,0442 -1,33 
hsa-miR-30b-5p MIMAT0000420 0,0445 2,02 
hsa-miR-885-5p MIMAT0004947 0,0446 1,42 
hsa-miR-4769-3p MIMAT0019923 0,0446 1,41 
hsa-miR-1323 MIMAT0005795 0,0446 1,24 
hsa-miR-1193 MIMAT0015049 0,0457 1,17 
hsa-miR-5580-3p MIMAT0022274 0,0459 -1,23 
hsa-miR-205-3p MIMAT0009197 0,0459 1,06 
hsa-miR-7849-3p MIMAT0030424 0,0460 1,11 
hsa-miR-383-3p MIMAT0026485 0,0463 -1,17 
hsa-miR-126-3p MIMAT0000445 0,0468 1,16 
hsa-miR-7150 MIMAT0028211 0,0470 1,32 
hsa-miR-3620-3p MIMAT0018001 0,0470 1,34 
hsa-miR-634 MIMAT0003304 0,0471 -1,33 
hsa-miR-6808-5p MIMAT0027516 0,0477 1,65 
hsa-miR-4759 MIMAT0019905 0,0485 -1,22 
hsa-miR-6729-5p MIMAT0027359 0,0486 1,16 
hsa-miR-6746-3p MIMAT0027393 0,0493 1,48 
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To explore the impact of E2-regulated miRNA in the context of our study, predicted 
target genes assigned to cardiovascular pathways by IPA software were selected and in silico 
functional characterization was performed. Top ten cardiovascular canonical pathways are 
listed in Table 3 in the order of p values. IPA software also determines significance of the 
association between the data set and a specific canonical pathway based on a ratio between 
the number of target genes from the data set that map to the pathway divided by the total 
number of genes that map to a specific canonical pathway. Ratios of most regulated canonical 
pathway are also shown in Table 3.
Target genes regulated by E2-dependent miRNA were associated to specific canonical 
pathways. The top pathways are related to cardiac hypertrophy (118 genes), including 
signalling and the role of NFAT (104 genes). The top network generated by IPA revealed the 
interactions of altered miRNA with signalling pathways such as thrombin (98 genes), CXCR4 
Table 3. Top 10 cardiovascular related Canonical Pathways regulated by E2-dependent miRNA. Selection 
and functional characterization of predicted target genes assigned to cardiovascular pathways were 
performed by IPA software and the top 10 were ordered according to their p value. Ratio represents the 
number of target genes from the data set that map to the pathway divided by the total number of genes that 
map to a specific canonical pathway. Number of target genes assigned to each canonical pathway are shown
Table 2. Regulatory networks modulated by E2-dependent miRNA. miRNA significantly regulated by E2 (1 
nmol/L) were analysed using IPA software. The score is used to rank networks according to how relevant 
they are to the genes in the input dataset
 
 
Top Diseases and Functions Score miRNA in Network Predicted targets in Network 
1 
Cell Death and Survival, 
Infectious Diseases, Organismal Development, 
27 
miR-1294, miR-526b-3p, miR-30b-5p, 
miR-3120-5p, miR-3620-3p, miR-3622b-3p, 
miR-3680-3p, miR-3684, miR-374a-3p, 
miR-378h, miR-4457, miR-4460, miR-5007-3p, 
miR-501-3p, miR-520g-3p, miR-6746-3p 
ABCG2, CAMK2N1, CCDC70, CCNE2, CNKSR2, DCUN1D5, DQX1, FCHO2, 
GNA13, MDP1, NT5C3A, PAPD4, PDCD1LG2, PFN2, PMAIP1, RPL17-
C18orf32, RRAGD, SDAD1, VLDLR 
2 
Lipid Metabolism, Small Molecule Biochemistry, 
Cellular Assembly and Organization 
21 
miR-1205, miR-126a-3p, miR-219a-5p, 
miR-383-3p, miR-4264, miR-4320, miR-448, 
miR-4759, miR-4797-3p, miR-577, 
miR-6841-5p, miR-876-5p, miR-92a-3p 
 
C17orf80, CALCR, CLNS1A, ENPP6, FBXO33, GNRH1, HSFY1/HSFY2, IGBP1, 
KCNA4, MRPL33, MYO1B, NAP1L3, PI4KA, PTF1A, RGS3, SNTG2, T, TBX21, 
UBE2W, VIL1, WFDC11, ZSCAN12 
3 
Reproductive System Development and Function, 
Organ Development, Developmental Disorder 
21 
miR-1253, miR-1287-5p, miR-1296-5p, 
miR-26a-5p, miR-6750-3p, miR-4491, 
miR-4680-3p, miR-487a-5p, miR-5008-3p, 
miR-506-5p, miR-1323, miR-5580-3p, 
miR-7-2-3p 
 
ART3, ASB9, CHORDC1, EGFL6, ELSPBP1, GTF2A1L, LOC100131655, 
MTERF4, PLAG1, PLGRKT, RPS27L, SMAD1, SNRNP48, SPDYA, SPINK13, 
SPRR2B, SPRR2D, STON1-GTF2A1L, TDRD7, TGFBR2, TRIT1, ZBTB37 
4 
Molecular Transport, Organismal Development, 
Behaviour 
16 
miR-1224-3p, miR-124-5p, miR-1303, 
miR-3160-5p, miR-34c-3p, miR-3914, 
miR-4769-3p, miR-548ae, miR-623, 
miR-6839-3p, miR-4739 
 
ABCD1, ARF6, ASAH2, BORCS6, BORCS8, BRMS1L, CARTPT, CD302, CRHBP, 
DEFB134, GPKOW, IGSF23, IRF2BP2, KBTBD6, KLHL7, LANCL1, NUPL2, 
PDGFRL, PDXP, RSU1, SLC13A3, TSSK3, TUBAL3, ZNF843 
5 
Cell Cycle, Cellular Compromise, Cellular Function 
and Maintenance 
16 
miR-1263, miR-4298, miR-522-3p, miR-4685-5p, 
miR-3689f, miR-4524b-5p, miR-4679, 
miR-4778-5p, miR-548c-3p, miR-553, miR-5684 
 
AKR1B10, ARMC10, C2CD4B, CPXM2, CSGALNACT2, CYTH3, DNASE2B, 
FAM46D, GSTCD, HSPA13, KIAA1586, KRTAP20-2, NAA15, NAA30, NUDT9, 
NUDT16L1, PHTF2, PPM1D, SFTPC, SLC22A7, SLC39A6, TCEA1, TRAK1, 
VRK3 
6 
Cell Morphology, Gastrointestinal Disease, 
Organismal Injury and Abnormalities 
15 
miR-6866-3p, miR-25-5p, miR-3124-5p, 
miR-4429, miR-3682-3p, miR-4291, 
miR-6512-5p, miR-6726-3p, miR-6800-3p, 
miR-922 
 
ARPC5L, C17orf49, C1QA, CASP1, CORO6, DLEU2L, ERCC8, FGFBP1, HIPK2, 
IL19, INO80C, JOSD2, KRTAP24-1, NKX6-2, OPRM1, OSGEPL1, POLR1C, 
RAB8A, RBM34, RGS22, TAPBP, TFF3, TMEM128, TMEM39A, TSSK6 
7 
Cardiovascular Disease, Cancer, Dermatological 
Diseases and Conditions 
15 
miR-3936, miR-8089, miR-4710, miR-5588-3p, 
miR-6734-5p, miR-6848-5p, miR-3125, 
miR-7158-5p, miR-5739, miR-937-3p 
 
AOC2, ARHGEF6, ATE1, CCDC85A, DCAKD, DLK2, DMWD, FOXD3, GRAMD4, 
HGS, HRC, LINC00346, MAPK15, ODF3L1, PEX19, PISD, PTCH1, PTCH2, 
RIMBP3, SH2D3C, SNRPA, SPRED3, ZFAND2A, ZFYVE28, ZNF687 
8 Auditory and Vestibular System Development and 
Function, Carbohydrate Metabolism, 
Cardiovascular Disease 
15 miR-2052, miR-6871-3p, miR-3975, 
miR-4632-5p, miR-4473, miR-508-3p, 
miR-512-3p, miR-634, miR-6782-5p, 
miR-6888-3p 
 
AADACL4, ABHD18, ARSF, ATOH1, AZIN1-AS1, CCP110, CYP4F3, DDI1, 
FGF13, GAS2, GCNT3, GIP, HNRNPR, HPRT1, LCP1, LRRC69, PDIK1L, 
PRMT6, RHBDD3, SLC26A6, SLC2A10, SMAD9, SMN1/SMN2, STXBP5L, 
WIPF3 9 
Cardiovascular Disease, Cardiovascular System 
Development and Function, Organ Morphology 
13 
miR-1973, miR-3170, miR-548al, miR-6729-5p, 
miR-6721-5p, miR-6808-5p, miR-6884-3p, 
miR-6886-5p, miR-7150 
 
CCDC12, COX4I2, FBXO46, GALNS, GLIS1, HAS2, HRH1, IFITM3, ITPKB, 
JADE2, KIF17, LCE5A, LY6L, MAF1, MAP2K2, MLLT1, NANOG, POR, PRAP1, 
TCF7L1, TGM6, TROAP, TRPC4AP, TUBB8, VANGL1, XPC 
10 Cell Cycle, Cellular Movement, Cancer 13 
miR-1244, miR-205-3p, miR-130a-5p, 
miR-302b-5p, miR-6754-3p, miR-4462, 
miR-6747-3p, miR-7849-3p, miR-885-5p 
 
BOD1, CLDN12, COMMD9, CYYR1, EIF1AY, EXOC1, KMT5A, LRRIQ4, MOG, 
PARL, PDK4, PROK2, RPS19BP1, RSPH10B/RSPH10B2, ST6GALNAC3, 
STARD3NL, STX12, THAP12, TMEM70, ZAR1L, ZDBF2, ZNF141, ZNF486, 
ZNF676, ZNF682, ZNF728 
 
 
 Canonical Pathways -log (p-value) Ratio Number of target genes 1 Cardiac Hypertrophy Signalling 131.0 0.50 118 
2 Role of NFAT in Cardiac Hypertrophy 116.0 0.53 104 
3 Thrombin Signalling 106.0 0.48 98 
4 CXCR4 Signalling 86.0 0.49 80 
5 Endothelin-1 Signalling 85.2 0.44 83 
6 Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 83.9 0.32 100 
7 Phospholipase C Signalling 83.6 0.38 91 
8 Protein Kinase A Signalling 81.6 0.27 107 
9 Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 79.1 0.42 80 
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(80 genes), phospholipase C (91 genes), protein kinase A (107 genes) and Rho GTPases (85 
genes). Moreover, the role of macrophages, fibroblasts and endothelial cells (100 genes) 
also appear between the main regulated pathways. Additionally, E2-regulated miRNA 
were related to endothelin-1 signalling (83 genes), nitric oxide (NO) and reactive oxygen 
species production (80 genes), key vasoactive compounds in the regulation of endothelial 
homeostasis that are usually related to the vascular effects of estrogens.
miRNA expression profiling and microarray validation
As describe above, differences between miRNA profiling of human endothelial cells 
exposed during 24 hours with or without 1 nmol/L E2 revealed a total of 114 miRNA 
significantly regulated, with fold changes ranging from -1.76 to 2.02. Fig. 3A shows the most 
differentially expressed miRNA with a fold-change greater than 1.5. Thirteen miRNA were 
differentially regulated by E2 with this fold-change selected, including 10 up-regulated and 
3 down-regulated miRNA. In order to validate our findings, qRT-PCR was performed using 
independently obtained RNA samples different from those used in microarray experiment. 
The most differentially expressed miRNA obtained in microarrays (miR-30b, miR-487a, miR-
4710, miR-501, miR-378h and miR-1244) were chosen and analysed by qRT-PCR. Obtained 
results confirmed microarray data of miRNA chosen for testing, including E2-dependent 
up-regulation of 4 miRNA (miR-30b, miR-487a, miR-4710 and miR-501) and the down-
regulation of 2 miRNA (miR-378h and miR-1244) (Fig. 3B).
Genomic location of validated E2-regulated miRNA.
As described before, miRNA sequences can be located in intronic regions of non-coding 
or coding transcripts, but it can be also encoded by exonic regions. We used miRIAD software 
to search genomic location of E2-dependent miRNA precursors. Table 4 shows chromosomic 
location and information about the host genes of intragenic miRNA. It is worthy to note that 
mature hsa-miR-1244 have 4 precursors sequences located in 3 different chromosomes.
Among the miRNA regulated by E2, there are 5 miRNA precursor sequences located 
between gene sequences and 4 intragenic miRNA precursor sequences: hsa-miR-501, hsa-
miR-378h and hsa-miR-1244-2 are intronic miRNA whereas hsa-miR-1244-1 is an exonic 
miRNA. Host genes of intragenic miRNA are also shown in Table 4: hsa-miR-501 is located in 
CLCN5, hsa-miR-378h in FAXDC2, hsa-miR-1244-1 in PTMA and hsa-miR-1244-2 in DTWD2.
Role of estrogen receptors in E2-modified miRNA
To study the role of ER in the expression of E2-dependent miRNA, both computational 
and experimental approaches were used. Firstly, we search in silico for putative ER binding 
Fig. 3. Validation of microarray data of E2-regulated miRNA in HUVEC. (A) miRNA expression profiling of 
differentially expressed miRNA obtained by microarray (fold change >1.5) in E2-treated HUVEC. Results 
are shown as fold change of 4 independent experiments. (B) The most regulated miRNA by E2 in HUVEC 
selected from microarray data were validated by qRT-PCR as described in Material and Methods. Results are 
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sites in the regulatory region 
of miRNA precursors. Also, 
pharmacological treatment 
of endothelial cells with ER 
antagonists and agonists was 
performed to evaluate the role of 
ER in E2-regulated miRNA.
Available online 
bioinformatics tools were used 
to search for ER putative binding 
sites within the regulatory region 
of miRNA, focused on the ER 
mainly acting as transcription 
factors (ERα and ERβ). We used 
miRStart database to predict the 
transcription start site (TSS) of 
the E2-regulated miRNA. Then, 
JASPAR 2016 server was used 
to predict ERα and ERβ binding 
sites for binding motifs drawn 
from the JASPAR database (Fig. 
4A). TSS of hsa-miR-4710, hsa-
miR-378h and hsa-miR-1244-4 
were not found in miRStart 
database, and were predicted 
using Promoter 2.0 Prediction 
Server. The location of TSS of the 
validated E2-regulated miRNA 
ranged from 109 bp distance from 
the precursor sequence of miR-
1244-2 up to 31696 bp distance 
from the miR-30b precursor (Fig. 
4B).
To predict ER binding sites 
in the promoter region of E2-
regulated miRNA, regulatory 
region was established based on 
genomic locality, upstream less 
than 10 kb from TSS. ER binding sites were found located in the regulatory region of all 
selected E2-regulated miRNA (Fig. 4B). Results showed a greater number of binding sites 
for ERβ than for ERα in the promoter region of selected miRNA precursors. However, since 
the sequence logo depicts the conservation of nucleotides in a specific position, the large 
number of ERβ binding sites found could be related to a greater variation observed in the 
sequence logo for the ERβ motif.
To evaluate experimentally the role of ER subtype in miRNA changes induced by E2, 
HUVEC were exposed to the non-selective antagonist of ERα and ERβ, ICI (1 μmol/L), 
the specific ERα antagonist MPP (1 μmol/L) and the specific GPER antagonist G15 (1 
μmol/L), before to E2 (1 nmol/L) exposition (Fig. 5). miR-30b-5p, miR-487a-5p and miR-
378h expression changes induced by E2 were abolished by ICI and MPP but not by G15 
treatment. Decreased miR-1244 expression induced by E2 was abrogated by MPP but no by 
ICI antagonist or G15 treatment. These results suggest a predominant role of ERα in miR-
30b-5p, miR-487a-5p, miR-378h and miR-1244 regulation. The increment in miR-501-3p 
expression observed when HUVEC was exposed to 1 nmol/L E2 was reverted by using the 
unspecific ER antagonist, but not by MPP or G15. This finding suggests a possible role of ERβ 
Table 4. miRNA precursor location of E2-regulated miRNA. 
miRIAD searched the location of miRNA precursors of E2-
dependent miRNA based in their miRBase accession number
 
 
Symbol Accession Location Intragenic Host gene Chromosome 
hsa-mir-30b MI0000441 NO - 8 
hsa-mir-487a MI0002471 NO - 14 
hsa-mir-4710 MI0017344 NO - 14 
hsa-mir-501 MI0003185 YES CLCN5 X 
hsa-mir-378h MI0016808 YES FAXDC2 5 
hsa-mir-1244-1 MI0006379 YES PTMA 2 
hsa-mir-1244-2 MI0015974 YES DTWD2 5 
hsa-mir-1244-3 MI0015975 NO - 12 
hsa-mir-1244-4 MI0031511 NO - 12 
 
 
Fig. 4. Putative ER binding sites in the regulatory region of the 
precursors of E2-regulated miRNA. (A) ERα and ERβ binding sites 
for binding motifs were drawn from the JASPAR database. The 
higher size of the nucleotide symbol represents a higher strict 
criteria. (B) The transcription start site (TSS) was identified with 
miRStart and is presented as base pairs (bp) before precursor. 
The number of ER binding sites found in promoter region of E2-





hsa-mir-30b	 31696	 1	 16	
hsa-mir-487a	 14000	 2	 41	
hsa-mir-4710	 20600	 4	 54	
hsa-mir-501	 5189	 1	 25	
hsa-mir-378h	 1900	 2	 34	
hsa-mir-1244-1	 5129	 2	 46	
hsa-mir-1244-2	 109	 2	 30	
hsa-mir-1244-3	 110	 3	 25	
hsa-mir-1244-4	 1000	 3	 28	
	
B
A ERα Sequence logo ERβ Sequence logo
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in the regulation of miR-501-3p levels in HUVEC. Finally, neither ICI nor MPP exposition had 
effect counteracting the increase of miR-4710 observed after E2 exposition, and only G15 
treatment abolished the E2-induced miR-4710 expression in HUVEC, suggesting the role of 
GPER in this expression.
Specific ER agonists were used to reinforce the role of specific ER in E2-regulated 
miRNA. HUVEC were exposed to the selective ERα agonist PPT (1 nmol/L), the selective 
ERβ agonist DPN (1 nmol/L) and the selective GPER agonist G1 (1 nmol/L) for 24 hours and 
the expression of validated miRNA were measured by qRT-PCR and compared to the effect 
of E2 (1 nmol/L; Fig. 6). Exposition of PPT, but not DPN or G1, stimulate miR-30b-5p and 


















































































































































































































Fig. 5. Role of ER antagonists in miRNA expression. HUVEC were exposed to ICI (1 µmol/L), MPP (1 µmol/L) 
or G15 (1 µmol/L) with or without E2 (1 nmol/L) for 24 h. Relative miRNA expression was measured by 
qRT-PCR as described in Material and methods. Data are expressed as mean ± SEM of n = 8-12 from 3 to 5 
independent experiments. *p<0.05; **p<0.01; ***p<0.001 vs. Control and #p< 0.05; ##p< 0.01 vs. ###p<0.001 
vs. E2.

























































































































































































Fig. 6. Role of ER agonists in miRNA expression. HUVEC were exposed to E2 (1 nmol/L), PPT (1 nmol/L), 
DPN (1 nmol/L) or G1 (1 nmol/L) for 24 h. Relative miRNA expression was measured by qRT-PCR as 
described in Material and methods. Data are expressed as mean ± SEM of n = 8-12 from 3 to 5 independent 
experiments. *p<0.05; ***p<0.01; ***p<0.001 vs. Control.
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miR-487a-5p expression. In addition, only PPT treatment decreased miR-378h levels. These 
findings are in agreement with results obtained using specific ERα antagonist and validate 
the role of ERα in the modulation of miR-30b-5p, miR-378h and miR-487a-5p. On the other 
hand, E2 induction of miR-4710 was mediated through GPER, since treatment with the 
specific GPER agonist G1 completely mimic E2 effect. Unpredictably, miR-501-3p expression 
was not significantly changed after isolated exposition with the different agonists. Finally, 
miR-1244 expression was decreased after exposition of the three different ER agonists.
Discussion
In the present study, we systematically investigated the role of E2 (1 nmol/L) on miRNA 
profile in human endothelial cells by combining microarray technology with bioinformatics 
analysis. With those tools, we found that physiological concentration of E2 induces a change 
in miRNA expression profile, which combined with predicted target genes reveal a potential 
link between E2 and miRNA in the regulation of endothelial function. We also found that E2 
effects on miRNA expression profile in HUVEC is differentially regulated by ER subtypes.
Functional in silico analysis of predicted targets of E2-regulated miRNA identified different 
biological processes that could modify endothelial function, including cellular morphology 
and mobility, cell cycle, cell death and survival, lipid and carbohydrate metabolism. In that 
sense, accordingly to the role of E2 in endothelial cell movement previously published [28], 
it has been recently described that increase in cell migration and proliferation of E2-exposed 
HUVEC is mediated by miR-126-3p regulation [29]. Cell cycle, cell death and survival have also 
been ranked in the principal E2-regulated networks. Indeed, E2 has already been implicated 
in apoptosis via activation of miRNA-23a and p53 in liver cancer [30], and different profiles 
of estrogen-regulated miRNA in breast cancer cells have been described [31].
In addition, lipid and carbohydrate metabolism has also been included among the most 
regulated networks by miRNA, according to results derived from mRNA microarray previously 
published in HUVEC [5]. The effect of estrogens on lipid and carbohydrate metabolism has 
been previously described in postmenopausal women using estrogen replacement therapy 
[32], and actions triggered by ER have been involved in cellular metabolism in different 
tissues [33]. Since miRNA play a role in metabolic disorders [34], it is feasible that the 
modification of miRNA profile by E2 could be among the mechanisms by which estrogens 
regulate lipid metabolism.
Furthermore, development and functions of reproductive system is also, and expected, 
among the most significant networks regulated by E2. Estrogen action has been related to 
regulation of specific miRNA expression in the mouse uterus [35], and in humans, changes 
in miRNA expression has also been described along different phases of endometrium [22], 
suggesting a hormonal regulation of miRNA involved in endometrial cycle.
Among the pathways associated to cardiovascular pathways, that related to cardiac 
hypertrophy signal is the top ranked canonical pathway. Small and Olson reviewed the specific 
signature patterns of miRNA associated to different cardiovascular disorders, including 
cardiac hypertrophy [36]. Several studies have described sex-associated differences in gene 
and protein expression in the heart and have attributed those changes to the direct action 
of estrogens via either ERα or ERβ on mRNA transcription [37]. However, considering that 
miRNA play an important role in regulating gene expression, this could be a new mechanism 
by which estrogen would regulate cardiac morphology. In fact, it has been previously reported 
a sex-specific profile of miRNA expression mediated by ERβ in hypertrophied hearts [38].
During the progression of cardiovascular diseases, endothelial dysfunction is a 
critical player. Clinical and basic studies have established sex-associated differences in the 
regulation of endothelial function, and the modulatory role of estrogen on the endothelium 
have been well described. In this study, we described another mechanism by which estrogen 
could contribute to the regulation of endothelial function, that is, via miRNA modulation. 
Three of the most important vasoactive mediators produced by the endothelium such as 
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NO, reactive oxygen species and endothelin-1 signalling, appear to be regulated by E2-
dependent miRNA. These results not only reinforce the role of E2 in NO stimulation, in the 
protection against reactive oxygen species and in the reduction of endothelin-1 [39], but 
also suggest new endothelial regulatory mechanisms by estrogens. Sex-differences in NO 
regulation by miRNA has been demonstrated in mouse hearts. The expression of miR-222 
was decreased in females compared to males, and correlated with increased endothelial NO 
synthase expression in females [40]. In this direction, other studies also have described that 
estrogens stimulates ERα-dependent inhibition of miR-22 expression, leading to an increase 
antioxidant activity in myocardium [41].
In the present study, we focused on miRNA that were highly changed after treatment 
with physiological concentration of E2 in HUVEC. Among the most modified miRNA, miR-
30b-5p, miR-487a-5p, miR-4710 and miR-501-3p were over-expressed after E2 treatment, 
while miR-378h and miR-1244 were down-regulated. miR-30b has been previously 
described as an estrogen-sensitive miRNA being increased by E2 treatment in breast cancer 
cells [42]. Moreover, miRNA profiling of human endometrium reveals cyclic changes in miR-
30b expression through the different physiological phases [43], and sex differences of miR-
30b levels were also observed in brains of female schizophrenic patients compared to males 
[44], suggesting the effect of physiological concentrations of estrogen on miR-30b regulation. 
In endothelial cells, miR-30 has also been implicated in angiogenesis processes [45], anti-
inflammatory effects by decreasing angiopoietin 2–induced VCAM1 expression [46] and 
apoptosis inhibition of human coronary artery endothelial cells [47]. In this regard, it is 
noteworthy that E2 has also pro-angiogenic, anti-inflammatory and anti-apoptotic properties 
in response to vascular injury [4]. miR-487a has been associated to the transforming growth 
factor β1 (TGF-β1) pathway [48, 49], a key cytokine in vascular function that has been 
previously related to estrogen action in endothelial cells [5]. On the other hand, our results 
showed miR-1244 as the most decreased miRNA in endothelial cells exposed to E2, which 
has been related to reduced migration of lung cancer cells [50]. As far as we know there 
is no published information about miRNA-1244, miR-501-3p, miR-4710 and miR-378h at 
cardiovascular level. However, miRNA-1244 is up-regulated in ER- compared to ER+ breast 
cancer cells [51], suggesting the role of estrogen receptor in decreasing miRNA-1244. miR-
501-3p has been related to pathological events occurring in Alzheimer disease brains [52].
The genomic effects of E2 are mainly mediated through the classical nuclear receptors 
ERα and ERβ, which function as ligand-activated transcription factors. In silico analysis of 
predicted target gene-transcription factor associations provided information about estrogen 
response element (ERE) sites in the regulatory region of the E2-regulated miRNA. ERE are 
15 bp palindromic sequence with high affinity to ER which are conserved across species. In 
our results, ERE sites were found located in the regulatory region of all selected E2-regulated 
miRNA, suggesting that estrogen may be a regulator of those miRNA. Different studies 
provide data about distribution of ER binding sites in the regulatory regions of estrogen-
responsive genes. Genome-wide mapping of ERE have shown that most of receptor binding 
sites were located close to TSS (1 kb), but they also appeared up to 10 kb up-stream from TSS 
[53]. However, Carroll et al. found that only 4% of ER binding sites mapped were located to 
1 kb promoter-proximal regions. Indeed, functional ERα binding sites have been described 
much further (up to 200 kb) from the estrogen-regulated genes [54]. Meanwhile, it has been 
described that, in general, ERβ-bound regions are located more closely to TSS [55].
Our results showed that E2-dependent regulation of the selected miRNA is mediated 
via ER. According to that, miRNA profiling between ER+ or ER- breast cancer cells revealed 
differences [51, 56]. In fact, Bailey et al. demonstrated that ER binding sites located near 
miRNA are lost in differentially decreased miRNA in ER- breast cancer cell line [56]. We have 
also demonstrated the implication of specific ER in the selected E2-induced miRNA. Most 
of the analysed miRNA were regulated by ERα, although ERβ and GPER were also involved 
in E2-regulated miRNA expression. Physiological responses require a balance between the 
activities of different ER, but several studies have reported differences in gene expression 
regulation mediated by either ERα or ERβ [57, 58]. Studies using ERα and ERβ KO mice reveal 
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that the beneficial effects of estrogens on vascular system are mediated by ERα [58, 59]. It 
has been also reported that vascular smooth muscle cells proliferation is inhibited through 
an ERα-dependent miR-203 up-regulation [60]. Specifically, estrogen action in endothelial 
cells is assumed to be mainly mediated by ERα [6, 7, 28].
Conclusion
Data presented in this study provides a systematic analysis of miRNA expression profile 
by E2 in human endothelial cells. Identification of biological processes related to E2-regulated 
miRNA has been described and the role of ER in miRNA expression has been demonstrated. 
Our results indicate that miRNA may act as crucial epigenetic regulators of gene expression 
in E2-treated human endothelial cells and make an important contribution to future research 
focus on characterizing the role of specific miRNA in vascular actions mediated by E2. They 
also could provide insight into the mechanisms by which sex hormones levels can contribute 
to sex-differences in cardiovascular diseases.
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